Leveraging targeted next-generation sequencing (tNGS) technology, this fully automated, end-to-end TB drug resistance detection solution — MTBseq™enables rapid, accurate testing directly on sputum and other samples without cell culture required. It helps to speed up the early detection of infectious sources, diagnosis of tuberculosis, know TB drug resistance and provide the guide for treatment.
This solution covers the entire workflow from nucleic acid extraction to data analysis, which can greatly facilitate your research work.
High efficient DNA extraction
Fully-automatic sequencing precedure
Onsite server for analysis and report issuing
Automatic library prep and report generation at low cost
Relatively less requirement of laboratory construction
20 drug-resistance genes; 17 anti-TB drugs; 8 MTBCs; 20 NTMs
Technical transfer offers on-site validation and training to support customer
| PARAMETERS | |||
| Sample type | Sputum, Bacterial cultures | ||
| Sample volume | ≥ 0.5 mL | ||
| Library preparation | multiplex PCR | ||
| Method | Targeted sequencing | ||
| Sequencing platform | FASTASeqTM S | FASTASeqTM 300 | SURFSeqTM 5000 |
| Number of samples/run（1 postive&1 negative control） | 1 FCL: 10 | 1 FCH : 96 | 1 FCM: 192 |
| 1 FCM: 18 | 1 FCP : 192 | 1 FCH: 768 | |
| Turnaround time* | 12.8/13.8 h | 26.5/49 h | 43/114 h |
| Reads requirement/sample | PE100, ≥ 2 M raw reads/sample | ||
| Report generation | Local analysis and report system | ||
*The calculation based on the automated workflow requires adjusting the specific time according to the sample number and is also related to the proficiency level of the personnel in each laboratory.
